MOREPENLAB

Morepen Laboratories Share Price

₹86.40 +0.03 (0.03%)

06 Dec, 2024 12:17

SIP TrendupStart SIP in MOREPENLAB

Start SIP

Performance

  • Low
  • ₹86
  • High
  • ₹88
  • 52 Week Low
  • ₹39
  • 52 Week High
  • ₹101
  • Open Price₹87
  • Previous Close₹86
  • Volume3,439,093

Investment Returns

  • Over 1 Month + 4.93%
  • Over 3 Month -7.55%
  • Over 6 Month + 92.64%
  • Over 1 Year + 97.26%
SIP Lightning

Smart Investing Starts Here Start SIP with Morepen Laboratories for Steady Growth!

Invest Now

Morepen Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 36.1
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 4,734
  • P/B Ratio
  • 5.6
  • Average True Range
  • 3.53
  • EPS
  • 2.4
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.57
  • RSI
  • 63.77
  • MFI
  • 85.67

Morepen Laboratories Financials

Morepen Laboratories Technicals

EMA & SMA

Current Price
₹86.40
+ 0.03 (0.03%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹80.52
  • 50 Day
  • ₹80.02
  • 100 Day
  • ₹75.70
  • 200 Day
  • ₹66.73

Resistance and Support

86.94 Pivot Speed
  • R3 90.33
  • R2 89.39
  • R1 87.88
  • S1 85.43
  • S2 84.49
  • S3 82.98

What's your outlook on Morepen Laboratories?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Morepen Laboratories Ltd. is a leading pharmaceutical company in India, specializing in Active Pharmaceutical Ingredients (APIs), formulations, diagnostics, and over-the-counter (OTC) products. It exports to over 75 countries, with a strong focus on APIs like Loratadine.

Morepen Laboratories has an operating revenue of Rs. 1,760.57 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 8% is okay, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 5% and 37% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 14% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 80 which is a GOOD score indicating consistency in earnings, a RS Rating of 82 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 49 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Morepen Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-11 Quarterly Results
2024-08-12 Quarterly Results
2024-05-21 Audited Results
2024-01-31 Quarterly Results
2023-11-02 Quarterly Results

Morepen Laboratories F&O

Morepen Laboratories Shareholding Pattern

35.65%
0%
0.94%
2.08%
0.68%
48.16%
12.49%

About Morepen Laboratories

  • NSE Symbol
  • MOREPENLAB
  • BSE Symbol
  • 500288
  • Chairman & Managing Director
  • Mr. Sushil Suri
  • ISIN
  • INE083A01026

Similar Stocks to Morepen Laboratories

Morepen Laboratories FAQs

Morepen Laboratories share price is ₹86 As on 06 December, 2024 | 12:03

The Market Cap of Morepen Laboratories is ₹4734.3 Cr As on 06 December, 2024 | 12:03

The P/E ratio of Morepen Laboratories is 36.1 As on 06 December, 2024 | 12:03

The PB ratio of Morepen Laboratories is 5.6 As on 06 December, 2024 | 12:03

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23